Published in final edited form as:

J Org Chem. 2013 June 21; 78(12): 6309–6315. doi:10.1021/jo400671q.

Palladium Catalyzed Intermolecular Aminoacetoxylation of Alkenes and the Influence of $\text{PhI}(\text{OAc})_2$ on Aminopalladation Stereoselectivity

Claudio Martínez[†], Yichen Wu[‡], Adam B. Weinstein[§], Shannon S. Stahl^{§,*}, Guosheng Liu^{‡,*}, and Kilian Muñiz^{†,¶}

Shannon S. Stahl: stahl@chem.wisc.edu; Guosheng Liu: gliu@mail.sioc.ac.cn; Kilian Muñiz: kmuniz@icq.es

[†]Institute of Chemical Research of Catalonia (ICIQ), 43007 Tarragona, Spain

[‡]Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai, 200032, P.R. China

[§]Department of Chemistry, University of Wisconsin–Madison, Madison, Wisconsin 53706, United States

[¶]Catalan Institution for Research and Advanced Studies (ICREA), Pg. Lluís Companys 23, 08010 Barcelona, Spain

Abstract

A modified protocol has been identified for Pd-catalyzed intermolecular aminoacetoxylation of terminal and internal alkenes that enables the alkene to be used as the limiting reagent. The results prompt a reassessment of the stereochemical course of these reactions. X-ray crystallographic characterization of two of the products, together with isotopic labeling studies, show that the amidopalladation step switches from a *cis*-selective process under aerobic conditions to a *trans*-selective process in the presence of diacetoxiodobenzene.

In recent years, a number of palladium-catalyzed methods have been reported for aminoacetoxylation¹ and diamination² of alkenes with diacetoxiodobenzene [$\text{PhI}(\text{OAc})_2$] as the stoichiometric oxidant. These difunctionalization reactions are initiated by nucleopalladation of the alkene,³ followed by $\text{PhI}(\text{OAc})_2$ -induced oxidative cleavage of the Pd–C bond, presumably via Pd^{III} or Pd^{IV} intermediates.⁴ In 2006, Liu and Stahl reported a method for intermolecular aminoacetoxylation of terminal alkenes that employs two equivalents of alkene with respect to the nitrogen nucleophile (Scheme 1a).^{1b} Recently, Martínez and Muñiz identified modified conditions that enabled regio- and diastereoselective intermolecular diamination of internal alkenes with the alkene as the limiting reagent (Scheme 1b).^{2c} Here, we show that similar modified conditions are effective in intermolecular aminoacetoxylation reactions (Scheme 1c). In the course of this work, we obtained new mechanistic insights into the stereochemical course of these reactions, which prompted a reassessment of the originally proposed mechanistic pathway. The data show that $\text{PhI}(\text{OAc})_2$ can alter the stereochemical course of the aminopalladation pathway relative to aerobic oxidative amination reactions.

*Corresponding Authors: kmuniz@icq.es; gliu@mail.sioc.ac.cn; stahl@chem.wisc.edu.

The authors declare no competing financial interest.

Supporting Information: ¹H NMR spectra for stereochemical analyses; ¹H and ¹³C NMR spectra of new compounds; X-ray crystallographic data. This material is available free of charge via the Internet at <http://pubs.acs.org/>.

The catalyst conditions recently reported for diamination of alkenes (Scheme 1b^{2c}) were used as a starting point to explore improved aminoacetoxylation conditions. Switching from $\text{PhI}(\text{OPiv})_2$ to $\text{PhI}(\text{OAc})_2$ as the oxidant enabled selectivity for aminoacetoxylation products (Scheme 1c). The scope of this reaction is similar to that observed for the diamination chemistry (Table 1). Representative terminal allyl ethers undergo the aminoacetoxylation in good yields (entries 1–4), as expected based on the earlier precedents. In addition, three allyl benzenes are successful (entries 5–7). These compounds are commonly difficult substrates in palladium catalysis, as they can undergo isomerization to the internal alkene in the presence of the palladium catalyst. Nevertheless, moderate yields could be obtained in the aminoacetoxylation reaction. Internal alkenes, such as (*Z*)- β -methylstyrene and (*Z*)-cinnamyl methyl ether, also undergo aminoacetoxylation without the formation of side products (entries 8–9). Only one diastereomer of the product is obtained.

The relative stereochemistry of compound **2i** was established by single-crystal X-ray diffraction analysis to be the *threo* isomer, and this product is formed exclusively under the optimized reaction conditions (Figure 1).⁵ This stereochemical assignment is opposite to that proposed in the aminoacetoxylation reactions reported previously.^{1b} The latter study proposed formation of *erythro*-**2i** on the basis of previously reported NMR characterization data for this compound.⁶ The single-crystal X-ray diffraction data reported here reveal that the NMR characterization data were inaccurate. Control experiments, summarized in Scheme 2, show that *threo*-**2i** is the sole aminoacetoxylation product obtained under several different catalytic conditions, including those from the original report by Liu and Stahl.^{1b} The stereochemical course of these aminoacetoxylation reactions match that of the diamination reaction in Scheme 1b, which was similarly supported by X-ray crystallography.^{2c}

The relative stereochemistry of product **2i** is controlled by the stereochemical course of the individual steps in the mechanism (Scheme 3). Following *cis*- or *trans*-aminopalladation of the alkene, oxidation of the Pd-alkyl species in the presence of $\text{PhI}(\text{OAc})_2$ is expected to generate a high-valent Pd-alkyl species that undergoes facile reductive elimination (for simplicity, the high-valent intermediate is illustrated as a Pd^{IV} species). This intermediate could undergo reductive elimination of the aminoacetoxylated product either by an $\text{S}_{\text{N}}2$ -type transition state with inversion of stereochemistry,⁷ or by a concerted three-centered transition state with retention of stereochemistry.^{8,9} Thus, *threo*-**2i** could be generated via *cis*-aminopalladation of the alkene and acetoxylation with retention of stereochemistry or *trans*-aminopalladation of the alkene and acetoxylation with inversion of stereochemistry.

Liu and Stahl previously tested the reactivity of substrate **1i** under aerobic oxidation conditions [i.e., in the absence of $\text{PhI}(\text{OAc})_2$], and found that a $\text{Pd}(\text{OAc})_2/\text{O}_2$ catalyst system converts **1i** into Wacker-type amination product (*Z*)-**3** in 20% yield (Scheme 4).^{1b} The conversion of **1i** to (*Z*)-**3** rather than (*E*)-**3** is indicative of a *cis*-aminopalladation pathway. No Wacker-type amination products are observed with **1i** under the aminoacetoxylation conditions. Formation of product *threo*-**2i** via *cis*-aminopalladation implies that C–O reductive elimination proceeds with retention of stereochemistry, which has limited precedent.¹⁰

The identity of the oxidant [O_2 vs. $\text{PhI}(\text{OAc})_2$] could influence the stereochemistry of the reactions, and we sought a substrate probe that could be used to assess the aminopalladation stereochemistry under aerobic vs. aminoacetoxylation reactions conditions. Fortuitously, substrate **1b** yields a small amount of the Wacker-type amination product **4** under aminoacetoxylation conditions (Scheme 5). This result enables the use of deuterated substrate (*E*)-**1b**-*d*₁ as a probe for the stereoselectivity of the aminopalladation step. Wacker-type oxidative amination could afford products (*E*)-**4**-*d*₁ or (*Z*)-**4**-*d*₁, and aminoacetoxylation

could afford *threo*-**2b**-*d*₁ or *erythro*-**2b**-*d*₁,¹¹ and the product identity can be used to gain insight into the stereochemical course of the reactions (Scheme 6).

Use of substrate (*E*)-**1b**-*d*₁ under aminoacetoxylation conditions yielded Wacker-type oxidative amination product (*Z*)-**4**-*d*₁ and a diastereomeric mixture of aminoacetoxylation products *threo*-**2b**-*d*₁ and *erythro*-**2b**-*d*₁ (Scheme 7a-b). Formation of enamide (*Z*)-**4**-*d*₁ is the product expected from *trans*-aminopalladation of the alkene. Since none of the *cis*-aminopalladation product (*E*)-**4**-*d*₁ is detected, the mixture of aminoacetoxylation products is believed to arise from poor stereoselectivity in the reductive elimination of the primary alkyl-Pd^{IV} intermediate. The origin of this poor selectivity is not presently understood.¹² When substrate (*E*)-**1b**-*d*₁ was subjected to aerobic conditions analogous to the aminoacetoxylation conditions (Scheme 7b vs. 7c), the oxidative amination product (*E*)-**4**-*d*₁ was observed as the sole product [5% yield; 70% recovered (*E*)-**1b**-*d*₁]. In spite of the poor yield, this product arises from a *cis*-aminopalladation pathway (cf. Scheme 6), consistent with the conclusion reached from the reaction of substrate **1i** under aerobic conditions in the previous study (cf. Scheme 4).^{1b,13}

Collectively, these results indicate that PhI(OAc)₂ alters the stereochemical course of the aminopalladation step. Prior studies have shown that ligands play a critical role in modulating of nucleopalladation stereoselectivity.¹⁴ Most germane to the reactivity described here, Weinstein and Stahl recently demonstrated that Pd(TFA)₂ exhibits greater proclivity for *trans*-aminopalladation relative to Pd(OAc)₂ in Wacker-type oxidative amidation reactions.^{14d} This trend can be rationalized by recognizing that substitution of an anionic ligand by an alkene in the *trans*-aminopalladation pathway will be more facile with less basic (i.e., less strongly coordinating) anionic ligands. Basic anionic ligands facilitate deprotonation of the amide nucleophile to afford a Pd-amidate intermediate that undergoes *cis*-aminopalladation of the alkene.¹⁵ In light of these considerations, we speculate that the Lewis acidic character of PhI(OAc)₂ facilitates displacement of acetate from Pd(OAc)₂ by the alkene and favors a *trans*-aminopalladation pathway.^{16,17}

Conclusions

We have identified reaction conditions that enable the alkene substrate to be used as the limiting reagent in the aminoacetoxylation of terminal and internal alkenes. Furthermore, we have obtained evidence that PhI(OAc)₂ influences the stereochemical course of Pd(OAc)₂-mediated aminopalladation of alkenes, shifting the reaction from a *cis*- to a *trans*-selective process.

Experimental Section

General considerations

MS (ESI-LCMS) experiments were performed using a C8 (5 cm x 4.6 mm, 5 μm particles) column with a linear elution gradient from 100% H₂O (0.5% HCO₂H) to 100% MeCN in 13 min at a flow rate of 0.5 mL/min.

General procedure for the aminoacetoxylation reaction (Table 1)

A Pyrex tube equipped with a stirrer bar is charged with 59 mg phthalimide (0.4 mmol, 1.0 eq) and 15 mg bis(benzonitrile)palladiumdichloride (0.04 mmol, 0.1 eq). Then, 0.6 mL of absolute dichloroethane are added via syringe and the solution is stirred at 70 °C for 1h. At this point, 260 mg iodosobenzene diacetate (0.80 mmol, 2.0 eq) and a previously prepared solution of 0.40 mmol of alkene with 14 mg of 4-*tert*-butylcatechol (0.08 mmol, 20%) are added. The resulting solution is sealed and stirred at 70 °C for 12h. After cooling to room temperature, the solution is washed with a 2%-solution of KOH (5 mL) and extracted with

CH₂Cl₂ (4 x 10 mL). The organic phases were combined, dried over Na₂SO₄ and evaporated under reduced pressure. The crude product was purified by chromatography (silica gel, neutralized with *n*-hexane/Et₃N (3%) and then *n*-hexane/ethyl acetate, 3/1, v/v) to give the pure product.

3-Butoxy-2-(1,3-dioxoisindolin-2-yl)propyl acetate (2a)—Obtained as colorless oil; 92 mg, 72% of yield. ¹H NMR (400 MHz, CDCl₃): δ = 0.84 (t, *J* = 7.4 Hz, 3H), 1.36–1.16 (m, 2H), 1.54–1.42 (m, 2H), 2.00 (s, 3H), 3.41 (dt, *J* = 9.3, 6.5 Hz, 1H), 3.48 (dt, *J* = 9.3, 6.5 Hz, 1H), 3.83 (dd, *J* = 10.0, 6.7 Hz, 1H), 3.91 (dd, *J* = 10.0, 8.1 Hz, 1H), 4.62–4.44 (m, 2H), 4.73 (tdd, *J* = 8.2, 6.6, 5.1 Hz, 1H), 7.74 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.86 (dd, *J* = 5.4, 3.1 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃): δ = 13.8, 19.1, 20.7, 31.6, 50.2, 61.7, 67.3, 70.9, 123.3, 131.8, 134.0, 168.3, 170.6. IR ν(cm⁻¹): 2958, 2932, 2871, 1743, 1709. HRMS: calcd for C₁₇H₂₁NO₅Na: 342.1317, found: 342.1304.

3-(Benzyloxy)-2-(1,3-dioxoisindolin-2-yl)propyl acetate (2b)—Obtained as colorless oil; 93 mg, 66% of yield. ¹H NMR (400 MHz, CDCl₃): δ = 2.00 (s, 3H), 3.89 (dd, *J* = 9.9, 6.4 Hz, 1H), 3.98 (dd, *J* = 9.9, 8.1 Hz, 1H), 4.64–4.44 (m, 4H), 4.86–4.73 (m, 1H), 7.42–7.13 (m, 5H), 7.74 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.86 (dd, *J* = 5.4, 3.1 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃): δ = 20.7, 50.2, 61.6, 66.7, 73.0, 123.4, 127.6, 127.7, 128.4, 131.8, 134.1, 137.6, 168.2, 170.6. IR ν(cm⁻¹): 3063, 3031, 2950, 2871, 1741, 1707. HRMS: calcd for C₂₀H₁₉NNaO₅: 376.1161, found: 376.1150.

3-Acetoxy-2-(1,3-dioxoisindolin-2-yl)propyl benzoate (2c)—Obtained as yellow oil; 104 mg, 71% of yield. ¹H NMR (400 MHz, CDCl₃): δ = 2.05 (s, 3H), 4.66 (dd, *J* = 6.9, 4.5 Hz, 2H), 4.75 (dd, *J* = 11.4, 5.7 Hz, 1H), 4.81 (dd, *J* = 11.4, 7.7 Hz, 1H), 4.90–4.96 (m, 1H), 7.41 (t, *J* = 7.8 Hz, 2H), 7.55 (t, *J* = 7.5 Hz, 1H), 7.76 (dd, *J* = 5.4, 3.0 Hz, 2H), 7.88 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.97 (d, *J* = 7.1 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃): δ = 20.8, 49.7, 61.3, 61.9, 123.6, 128.5, 129.9, 131.7, 133.3, 134.4, 166.1, 168.1, 170.6. IR ν(cm⁻¹): 3023, 2961, 2929, 1175, 1711, 1601. HRMS: calcd for C₂₀H₁₇NNaO₆: 390.0954, found: 390.0936.

2-(1,3-Dioxoisindolin-2-yl)-3-(octyloxy)propyl acetate (2d)—Obtained as yellow oil; 60 mg, 40% of yield. ¹H NMR (400 MHz, CDCl₃): δ = 0.87 (t, *J* = 7.1 Hz, 3H), 1.18–1.28 (m, 10H), 1.48–1.51 (m, 2H), 2.01 (s, 3H), 3.40 (dt, *J* = 9.3, 6.6 Hz, 1H), 3.49 (dt, *J* = 9.1, 6.4 Hz, 1H), 3.83 (dd, *J* = 10.0, 6.0 Hz, 1H), 3.93 (dd, *J* = 10.0, 8.3 Hz, 1H), 4.47–4.57 (m, 2H), 4.71–4.77 (m, 1H), 7.75 (dd, *J* = 5.5, 3.1 Hz, 2H), 7.87 (dd, *J* = 5.4, 3.0 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃): δ = 14.2, 20.9, 22.8, 26.2, 29.3, 29.5, 29.6, 31.9, 50.3, 61.8, 67.4, 71.4, 123.5, 131.9, 134.2, 168.4, 170.8. IR ν(cm⁻¹): 2926, 2855, 1776, 1710. HRMS: calcd for C₂₁H₂₉NNaO₅: 398.1943, found: 398.1940.

2-(1,3-Dioxoisindolin-2-yl)-3-phenylpropyl acetate (2e)—Obtained as colorless oil; 73 mg, 56% of yield. ¹H NMR (400 MHz, CDCl₃): δ = 1.99 (s, 3H), 3.20 (dd, *J* = 13.9, 6.4 Hz, 1H), 3.36 (dd, *J* = 14.0, 10.0 Hz, 1H), 4.50 (dd, *J* = 11.3, 4.7 Hz, 1H), 4.62 (dd, *J* = 11.3, 9.3 Hz, 1H), 4.88–4.75 (m, 1H), 7.37–7.08 (m, 5H), 7.70 (dd, *J* = 5.5, 3.0 Hz, 2H), 7.79 (dd, *J* = 5.4, 3.1 Hz, 2H). ¹³C NMR (126 MHz, CDCl₃): δ = 20.7, 34.9, 51.8, 63.4, 123.2, 126.8, 128.6, 128.9, 131.6, 133.9, 136.8, 168.2, 170.6. IR ν(cm⁻¹): 3062, 3028, 2927, 1771, 1707. HRMS: calcd for C₁₉H₁₇NNaO₄: 346.1055, found: 346.1067.

3-(2-(Benzyloxy)phenyl)-2-(1,3-dioxoisindolin-2-yl)propyl acetate (2f)—Obtained as yellow oil; 90 mg, 50% of yield. ¹H NMR (400 MHz, CDCl₃): δ = 1.93 (s, 3H), 3.30 (dd, *J* = 7.8, 5.1 Hz, 2H), 4.47 (dd, *J* = 11.2, 4.9 Hz, 1H), 4.63 (dd, *J* = 11.3, 9.1 Hz, 1H), 4.93–4.99 (m, 1H), 5.06–5.12 (m, 2H), 6.75 (t, *J* = 7.2 Hz, 1H), 6.86 (d, *J* = 8.1 Hz,

1H), 7.06 (dd, $J = 7.4, 1.7$ Hz, 1H), 7.12 (td, $J = 7.9, 1.7$ Hz, 1H), 7.33 (d, $J = 7.3$ Hz, 1H), 7.40 (t, $J = 7.6$ Hz, 2H), 7.49 (d, $J = 7.3$ Hz, 2H), 7.66 (dd, $J = 5.5, 3.0$ Hz, 2H), 7.74 (dd, $J = 5.4, 3.0$ Hz, 2H). **^{13}C NMR (126 MHz, CDCl_3):** $\delta = 20.8, 30.6, 50.5, 63.9, 70.2, 111.8, 120.8, 123.2, 125.8, 127.4, 127.9, 128.4, 128.6, 130.9, 131.8, 133.9, 137.2, 156.9, 168.3, 170.6$. **IR $\nu(\text{cm}^{-1})$:** 3064, 3030, 2929, 2871, 1738, 1708. **HRMS:** calcd for $\text{C}_{26}\text{H}_{23}\text{NNaO}_5$: 452.1474, found: 452.1474.

2-(1,3-Dioxoisindolin-2-yl)-3-(2-methoxyphenyl)propyl acetate (2g)—Obtained as yellow oil; 76 mg, 51% of yield. **^1H NMR (400 MHz, CDCl_3):** $\delta = 1.98$ (s, 3H), 3.19–3.28 (m, 2H), 3.79 (s, 3H), 4.48 (dd, $J = 11.4, 4.7$ Hz, 1H), 4.68 (dd, $J = 11.4, 9.6$ Hz, 1H), 4.90 (tdd, $J = 9.3, 6.3, 4.7$ Hz, 1H), 6.76 (td, $J = 7.4, 1.1$ Hz, 1H), 6.80 (dd, $J = 8.3, 1.0$ Hz, 1H), 7.06 (dd, $J = 7.5, 1.8$ Hz, 1H), 7.15 (td, $J = 7.9, 1.8$ Hz, 1H), 7.69 (dd, $J = 5.5, 3.0$ Hz, 2H), 7.79 (dd, $J = 5.4, 3.1$ Hz, 2H). **^{13}C NMR (126 MHz, CDCl_3):** $\delta = 20.9, 30.5, 50.6, 55.3, 63.7, 110.4, 120.5, 123.2, 125.4, 128.4, 130.9, 131.9, 133.9, 157.8, 168.4, 170.7$. **IR $\nu(\text{cm}^{-1})$:** 3020, 2959, 2937, 1774, 1709. **HRMS:** calcd for $\text{C}_{20}\text{H}_{19}\text{NNaO}_5$: 376.1161, found: 376.1168.

2-(1,3-Dioxoisindolin-2-yl)-1-phenylpropylacetate (2h)—Obtained as a white solid; 105 mg, 81% of yield. **m.p:** 112–113 °C ($\text{CH}_2\text{Cl}_2/\text{hexane}$). **^1H NMR (400 MHz, CDCl_3):** $\delta = 1.60$ (d, $J = 6.9$ Hz, 3H), 2.10 (s, 3H), 4.75 (dq, $J = 9.1, 6.9$ Hz, 1H), 6.30 (d, $J = 9.2$ Hz, 1H), 7.14–7.21 (m, 3H), 7.33 (dd, $J = 8.1, 1.6$ Hz, 2H), 7.62 (dd, $J = 5.4$ and 3.0 Hz, 2H), 7.69 (dd, $J = 5.4, 3.0$ Hz, 2H). **^{13}C NMR (126 MHz, CDCl_3):** $\delta = 15.3, 21.3, 50.4, 76.2, 123.2, 127.8, 128.4, 128.6, 131.6, 134.0, 137.5, 167.8, 169.9$. **IR $\nu(\text{cm}^{-1})$:** 3035, 2984, 2927, 2854, 1770, 1704. **HRMS:** calcd for $\text{C}_{19}\text{H}_{17}\text{NO}_4\text{Na}$: 346.1055, found: 346.1072.

Synthesis of deuterated substrate probe (*E*)-1b- d_1

A solution of KOH (2.69 g, 48 mmol) in DMSO (25 mL) was cooled in an ice bath and treated sequentially with benzyl alcohol (6.48 g, 60 mmol) and propargyl bromide (4.76 g, 40 mmol). The reaction mixture was stirred for 1 h at r.t. before being diluted with Et_2O and H_2O . The organic layer was separated, washed with H_2O , dried (Na_2SO_4), filtered, and concentrated in vacuo. Flash chromatography afforded benzyl propargyl ether (5.07 g, 87 %).

The benzyl propargyl ether (1.46 g, 10 mmol) was treated with $(\text{C}_5\text{H}_5)_2\text{ZrHCl}$ (Schwartz reagent, 3.23 g, 12.5 mmol) in anhydrous THF (45 mL). After 10 min, the solution turned black, and the reaction was then quenched with D_2O (7.4 mL), and stirring was continued overnight. The mixture was then diluted with Et_2O , dried over MgSO_4 , filtered and concentrated. The mixture was then purified by chromatography giving 1.26 g (86 %) of the product.

Compound (*E*)-1b- d_1 is a known compound.¹⁸ **^1H NMR (400 MHz, CDCl_3):** δ 7.30 (m, 5H), 5.96 (dt, $J = 17.2, 6, 1.6$ Hz), 5.30 (dt, $J = 17.2, 1.6$ Hz, 1H), 4.53 (s, 2H), 4.03 (dd, $J = 6, 4.4$ Hz, 2H). **^{13}C NMR (100 MHz, CDCl_3):** δ 138.3, 134.6, 128.4, 127.7, 127.6, 72.1, 71.1 (t, $J = 1.9$ Hz).

Procedures for the reaction of deuterated substrate (*E*)-1b-*d*₁ (Scheme 7)

Stereochemical assignments of products (*Z*)-4-*d*₁ and (*E*)-4-*d*₁ were achieved from NOESY-1D analysis of **4**¹⁹ (see the supporting information). The stereochemical assignments of products *erythro*-2b-*d*₁ and *threo*-2b-*d*₁ were achieved after derivatization and ¹H NMR spectroscopic analysis (see below and the supporting information).

(a) With PhI(OAc)₂ as oxidant—In a dried glass tube, Pd(CH₃CN)₂Cl₂ (5.2 mg, 0.02 mmol, 10 mol %), PhI(OAc)₂ (128.8 mg, 0.04 mmol, 2 equiv.), phthalimide (29.4 mg, 0.2 mmol, 1.0 equiv.) were dissolved in DCE (0.25 mL), and then (*E*)-1b-*d*₁ (59.6 mg, 0.4 mmol, 2.0 equiv.) was added. After the reaction mixture was stirred at 70 °C for 24 h, the residue was purified by column chromatography on silica gel with a gradient eluant of petroleum ether and ethyl acetate to afford (*Z*)-4-*d*₁, *erythro*-2b-*d*₁ and *threo*-2b-*d*₁.

(b) With O₂ as the oxidant—In a dried glass tube, Pd(OAc)₂ (4.5 mg, 0.02 mmol, 10 mol %), phthalimide (29.4 mg, 0.2 mmol, 1.0 equiv.) were dissolved in DCE (0.4 mL), charged with oxygen and then (*E*)-1b-*d*₁ (59.6 mg, 0.4 mmol, 2 equiv.) was added. After the reaction mixture was stirred at 70 °C for 18 h, the residue was purified by column chromatography on silica gel with a gradient eluant of petroleum ether and ethyl acetate to afford (*E*)-4-*d*₁.

¹H NMR (400 MHz, CDCl₃): δ 7.88 (m, 2H), 7.75 (m, 2H), 7.27 (m, 5H), 5.65 (s, 1H), 4.53 (s, 2H), 4.36 (s, 2H).

¹H NMR (400 MHz, CDCl₃): δ 7.88 (m, 2H), 7.75 (m, 2H), 7.27 (m, 5H), 5.43 (s, 1H), 4.54 (s, 2H), 4.35 (s, 2H).

¹H NMR (400 MHz, CDCl₃) δ 1.98 (s, 3H), 3.87 (dd, *J* = 6.4, 3.6 Hz, 1H), 3.96 (dd, *J* = 80, 1.6 Hz, 1H), 4.48–4.57 (m, 3H), 4.74–4.81 (m, 1H), 7.24–7.28 (m, 5H), 7.71–7.74 (m, 2H), 7.83–7.85 (m, 2H). ¹³C NMR (100 MHz, CDCl₃) δ 20.7, 50.0, 61.2 (t, *J* = 22.4 Hz), 66.6, 72.9, 123.3, 127.6, 127.7, 128.3, 131.7, 134.0, 137.5, 168.2, 170.6. HRMS: calcd for C₂₀H₂₂DN₂O₅: 372.1664, found: 372.1668. IR ν(cm⁻¹): 3088, 3063, 3031, 2868, 1740, 1708.

The structure of isomers *erythro-2b-d₁* and *threo-2b-d₁* were characterized by conversion to a heterocyclic product with diagnostic *J*-coupling and chemical shift differences. Protio-derivative **2b** was converted to **5b**²⁰ to identify the chemical shifts of the two protons H^{1a} and H^{2a}. The chemical shifts of H^{1a} and H^{2a} were assigned based on the *J*-values in the ¹H NMR spectrum of **5b** in benzene-*d*₆ (see figure S3 in the supporting information). **2b-d₁** was similarly converted to **5b-d₁**, and the ratio of H^{1b} : H^{2b} corresponded to the ratio of isomers *erythro-2b-d₁* : *threo-2b-d₁* (see figure S4 in the supporting information).

¹H NMR (400 MHz, C₆D₆) δ 7.15 (m, 5H), 6.19 (br, s, 1H), 4.07 (s, 2H), 3.58 (dd, *J* = 8.7, 8.7 Hz, 1H), 3.46 (dd, *J* = 8.7, 5.3 Hz, 1H), 3.13 (m, 1H), 2.70 (m, 2H).

¹H NMR (400 MHz, C₆D₆) δ 7.15 (m, 5H), 6.26 (br, s, 1H), 4.07 (s, 2H), 3.56 (d, *J* = 8 Hz, 0.42H), 3.45 (d, *J* = 5.2 Hz, 0.57H), 3.13 (dt, *J* = 6, 6 Hz, 1H), 2.75–2.67 (m, 2H).

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

KM and CM thank the Spanish Ministerio de Economía y Competitividad (CTQ2011-25027) for financial support. The authors thank Dr. J. Benet-Buchholz, Dr. E. C. Escudero-Adán, Dr. M. Martínez-Belmonte and Dr. E. Martín for the crystal structure analyses. YW and GL thank National Natural Science Foundation of China (No. 21202185) for financial support. ABW and SSS thank the NIH (R01 GM067173) for financial support.

References

- Alexanian EJ, Lee C, Sorensen EJ. J Am Chem Soc. 2005; 127:7690–7691. [PubMed: 15913354]
Liu G, Stahl SS. J Am Chem Soc. 2006; 128:7179–7181. [PubMed: 16734468] For a related aminoetherification reaction, see: Desai LV, Sanford MS. Angew Chem Int Ed. 2007; 46:5737–5740.

2. (a) Iglesias A, Pérez EG, Muñiz K. *Angew Chem Int Ed.* 2010; 49:8109–8111. (b) Muñiz K, Kirsch J, Chávez P. *Adv Synth Catal.* 2011; 353:689–694. (c) Martínez C, Muñiz K. *Angew Chem Int Ed.* 2012; 51:7031–7034.
3. (a) Zeni G, Larock RC. *Chem Rev.* 2004; 104:2285–2309. [PubMed: 15137792] (b) Beccali EM, Broggini G, Martinelli M, Sottocornola S. *Chem Rev.* 2007; 107:5318–5365. [PubMed: 17973536] (c) Minatti A, Muñiz K. *Chem Soc Rev.* 2007; 36:1142–1152. [PubMed: 17576481] (d) Kotov V, Scarborough CC, Stahl SS. *Inorg Chem.* 2007; 46:1910–1923. [PubMed: 17348722] (e) Jensen KH, Sigman MS. *Org Biomol Chem.* 2008; 6:4083–4088. [PubMed: 18972034] (f) McDonald RI, Liu GS, Stahl SS. *Chem Rev.* 2011; 111:2981–3019. [PubMed: 21428440]
4. For leading references, see: Canty AJ, Denney MC, Skelton BW, White AH. *Organometallics.* 2004; 23:1122–1131. Dick AR, Kampf JW, Sanford MS. *J Am Chem Soc.* 2005; 127:12790–12791. [PubMed: 16159259] Powers DC, Ritter T. *Nat Chem.* 2009; 1:302–209. [PubMed: 21500602] Deprez NR, Sanford MS. *J Am Chem Soc.* 2009; 131:11234–11241. [PubMed: 19621899] Powers DC, Lee E, Ariafard A, Sanford MS, Yates BF, Canty AJ, Ritter T. *J Am Chem Soc.* 2012; 134:12002–12009. [PubMed: 22804682] Powers DC, Ritter T. *Acc Chem Res.* 2012; 45:840–850. [PubMed: 22029861] Muñiz K. *Angew Chem Int Ed.* 2009; 48:9412–9423. Hickman AJ, Sanford MS. *Nature.* 2012; 484:177–185. [PubMed: 22498623]
5. Additionally, single crystal X-ray analysis of **2h** also established the relative stereochemistry to be *threo*, which suggests a unified pathway for internal alkenes (see the supporting information for details).
6. Fles D, Majhofer B, Kovac M. *Tetrahedron.* 1968; 24:3053–3057.
7. Sibbald PA, Rosewall CF, Swartz RD, Michael FE. *J Am Chem Soc.* 2009; 131:15945–15951. [PubMed: 19824646] Iglesias Á, Álvarez R, de Lera AR, Muñiz K. *Angew Chem Int Ed.* 2012; 51:2225–2228. Reductive elimination from Pd^{IV}–alkyl complexes with inversion of stereochemistry is also supported by analogy to fundamental studies of Pt^{IV}–alkyl complexes: Williams BS, Goldberg KI. *J Am Chem Soc.* 2001; 123:2576–2587. [PubMed: 11456927] Stahl SS, Labinger JA, Bercau JE. *Angew Chem Int Ed.* 1998; 37:2182–2192. and references therein.
8. Byers PK, Canty AJ, Crespo M, Puddephatt RJ, Scott JD. *Organometallics.* 1988; 7:1363–1367.
9. For examples of discrete Pd^{II} complexes in which oxidative cleavage of a Pd^{II}–C bond may proceed with either inversion or retention of stereochemistry, see: Coulson DR. *J Am Chem Soc.* 1969; 91:200–202. Wong PK, Stille JK. *J Organomet Chem.* 1974; 70:121–132. Bäckvall JE. *Tetrahedron Lett.* 1977; 18:467–468. Bäckvall JE. *Tetrahedron Lett.* 1978; 19:163–166. Zhu G, Ma S, Lu X, Huang Q. *J Chem Soc, Chem Commun.* 1995:271–273.
10. Desai LV, Hull KL, Sanford MS. *J Am Chem Soc.* 2004; 126:9542–9543. [PubMed: 15291549] For a relevant precedent involving C_{sp3}–O reductive elimination from Pt^{IV}, see: Khusnutdinova JR, Newman LL, Zavalij PY, Lam YF, Vedernikov AN. *J Am Chem Soc.* 2008; 130:2174–2175. [PubMed: 18220400]
11. Substrate (*E*)-**1b-d** also avoids the complication associated with potential reversible β-hydride elimination leading to a more thermodynamically favored product rather than the diagnostic alkene isomer. For example, substrate **1i** could exhibit this complication, as depicted below (we thank Prof. Datong Song, University of Toronto, for drawing our attention to this potential complexity):

12. The poor diastereoselectivity observed for reductive elimination of aminoacetoxylation product *erythro*- vs. *threo*-**2b** contrasts the excellent stereoselectivity observed for reductive elimination of aminoacetoxylation product *threo*-**2i** (cf. Scheme 3) and products derived from other internal alkene substrates. Presumably, the different selectivity is associated with the different reactivity of secondary benzylic vs. primary aliphatic alkyl–Pd intermediates.
13. A similar analysis of *cis*- vs. *trans*-aminopallation has been employed in the aminoetherification reaction in ref. 1c.
14. For discussion of the factors that contribute to nucleopalladation stereoselectivity, see reference 3f and Nakhla JS, Kampf JW, Wolfe JP. *J Am Chem Soc.* 2006; 128:2893–2901. [PubMed: 16506768] Liu G, Stahl SS. *J Am Chem Soc.* 2007; 129:6328–6335. [PubMed: 17439217] Keith JA, Henry PM. *Angew Chem Int Ed.* 2009; 48:9038–9049. Weinstein AB, Stahl SS. *Angew Chem Int Ed.* 2012; 51:11505–11509.
15. For further analysis of anionic ligand effects in amidopalladation reactions, see: Ye X, Liu G, Popp BV, Stahl SS. *J Org Chem.* 2011; 76:1031–1044. [PubMed: 21250706] Ye X, White PB, Stahl SS. *J Org Chem.* 2013; 78:2083–2090. [PubMed: 23157332]
16. NMR spectroscopic analysis of solutions of Pd(OAc)₂ and PhI(OAc)₂ did not provide evidence for a ground-state interaction between these species, but this result cannot exclude a kinetic effect in which iodine(III) facilitates displacement of acetate by an alkene.
17. Reactions between phthalimide and PhI(OAc)₂ could afford hypervalent iodine–phthalimide adducts, such as PhI(OAc)(NPhth) and PhI(NPhth)₂; however, it is not clear how the formation of such species would alter the stereochemical course of amidopalladation of the alkene. For references describing species such as PhI(OAc)(NPhth) and PhI(NPhth)₂, see the following: Hadjirapoglou L, Spyroudis S, Varvoglis A. *Synthesis.* 1983:207–208. Kim HJ, Kim J, Cho SH, Chang S. *J Am Chem Soc.* 2011; 133:16382–16385. [PubMed: 21928852] Moriyama K, Ishida K, Togo H. *Org Lett.* 2012; 14:946–949. [PubMed: 22273472]
18. Yagi K, Oikawa H, Ichihara A. *Biosci Biotech Bioch.* 1997; 61:1038–1040.
19. **4** is a known compound: Rogers MM, Kotov V, Chatwichien J, Stahl SS. *Org Lett.* 2007; 9:4331–4334. [PubMed: 17887694]
20. Product **5b** is a known compound. The ¹H NMR was consistent with the data in the literature: Bégis G, Cladingboel DE, Jerome L, Motherwell WB, Sheppard TD. *Eur J Org Chem.* 2009:1532–1548.

Figure 1.
X-Ray Crystal Structure of *threo-2i*.

Previous work: **This work:**

Scheme 1.
1,2-Difunctionalization of Alkenes

Scheme 2.

Exclusive formation *threo*-**2i** across related catalyst systems.

Scheme 3.
Stereochemical Pathways for the Aminoacetoxylation of Substrate **1i**.

Scheme 4. Oxidative Amination of Substrate **1i** Under Aerobic Conditions (ref. 1b).

Scheme 6. Stereochemical Pathways for the Reaction of Deuterated Substrate $(E)\text{-1b-d}_1$.

Scheme 7.
Reaction of Deuterated Substrate **4-d₁** Under Aminoacetoxylation and Aerobic Amidation Conditions.

Table 1

Aminoacetoxylation of Alkenes

$$\begin{array}{ccc}
 \text{PdCl}_2(\text{NPh})_2 \text{ (10 mol\%)} \\
 \text{phthalimide (1 equiv)} \\
 \text{PhI(OAc)}_2 \text{ (2 equiv)} \\
 \text{tert-butylcatechol (20 mol\%)} \\
 \text{DCE, 20 h, 70 }^\circ\text{C}
 \end{array}
 \xrightarrow{\hspace{1cm}}$$

entry	alkene	product	yield (%) ^a
1	1a	2a	72
2	1b	2b	66
3	1c	2c	71
4	1d	2d	40
5	1e	2e	56
6	1f	2f	50
7	1g	2g	51
8	1h	2h	81
9	1i	2i	61

^a Isolated yield after chromatography